Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.16869 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Risk Factors for Dupilumab-Associated Ocular Sequelae in the Treatment of Atopic Dermatitis.
Cureus
December 2024
Ophthalmology, SightMD, Babylon, USA.
Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and is used in the treatment of moderate-to-severe atopic dermatitis (AD) in those six months or older who are uncontrolled on or cannot tolerate topical treatments. Ocular surface disease is a recognized adverse effect of dupilumab, yet few studies describe the risk factors for developing ocular adverse effects. There are no standardized recommendations for monitoring patients on this medication.
View Article and Find Full Text PDFRecalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily.
J Clin Aesthet Dermatol
January 2025
Dr. Warren and Ms. Sanchez are with Derm Texas in Dallas, Texas.
Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may be more visible in darker skin toned patients. Vitiligo affects approximately 2 percent of children and adolescents in the United States, with half of the affected cases undiagnosed.
View Article and Find Full Text PDFEnglish version of clinical practice guidelines for the management of atopic dermatitis 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Article Synopsis
- The 2024 clinical practice guidelines for atopic dermatitis (AD) focus on effectively managing this condition characterized by itchy, relapsing eczema.
- The primary goal of treatment is to quickly induce remission by reducing skin inflammation and itching, primarily using topical anti-inflammatory medications.
- The updated guidelines introduce five new treatments and emphasize the importance of evaluating research and weighing the pros and cons of various medical options to enhance patient outcomes.
Concurrent Refractory Atopic Dermatitis and Generalized Vitiligo Successfully Treated with Abrocitinib: A Case Report.
J Asthma Allergy
December 2024
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Atopic dermatitis (AD) may sometimes be comorbid with vitiligo. However, these therapeutic agents are often slow acting and lead to various adverse effects, resulting in poor patient compliance. This report describes a 65-year-old male patient with refractory moderate-to-severe atopic dermatitis (AD) and generalized vitiligo.
View Article and Find Full Text PDFPrevalence and causes of subacute cough in Japan.
Respir Investig
January 2025
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawazumi Mizuho-machi, Nagoya, 467-860, Japan.
Article Synopsis
- Subacute cough is a specific type of cough lasting 3-8 weeks and is primarily caused by cough variant asthma, atopic cough, and sinobronchial syndrome, rather than post-infectious cough as previously believed.
- In a study involving 148 patients, 68.3% developed chronic cough, often stemming from multiple underlying conditions such as cough variant asthma combined with atopic cough.
- The findings highlight the need for careful diagnosis and treatment of multiple causes in patients with subacute cough to prevent progression to chronic cough.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!